Annual accounts receivable:
$308.45M+$74.25M(+31.70%)Summary
- As of today (September 5, 2025), HALO annual accounts receivable is $308.45 million, with the most recent change of +$74.25 million (+31.70%) on December 31, 2024.
- During the last 3 years, HALO annual accounts receivable has risen by +$217.48 million (+239.05%).
- HALO annual accounts receivable is now at all-time high.
Performance
HALO Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$316.34M+$11.72M(+3.85%)Summary
- As of today (September 5, 2025), HALO quarterly accounts receivable is $316.34 million, with the most recent change of +$11.72 million (+3.85%) on June 30, 2025.
- Over the past year, HALO quarterly accounts receivable has increased by +$101.81 million (+47.46%).
- HALO quarterly accounts receivable is now at all-time high.
Performance
HALO Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
HALO Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +31.7% | +47.5% |
| 3 y3 years | +239.1% | +67.0% |
| 5 y5 years | +418.9% | +745.8% |
HALO Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +239.1% | at high | +67.0% |
| 5 y | 5-year | at high | +418.9% | at high | +745.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
HALO Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $316.34M(+3.8%) |
| Mar 2025 | - | $304.62M(-1.2%) |
| Dec 2024 | $308.45M(+31.7%) | $308.45M(+7.9%) |
| Sep 2024 | - | $285.74M(+33.2%) |
| Jun 2024 | - | $214.52M(+9.5%) |
| Mar 2024 | - | $195.90M(-16.4%) |
| Dec 2023 | $234.21M(+1.4%) | $234.21M(+7.8%) |
| Sep 2023 | - | $217.32M(-11.7%) |
| Jun 2023 | - | $246.18M(+26.3%) |
| Mar 2023 | - | $194.88M(-15.7%) |
| Dec 2022 | $231.07M(+154.0%) | $231.07M(-1.0%) |
| Sep 2022 | - | $233.30M(+23.2%) |
| Jun 2022 | - | $189.37M(+66.5%) |
| Mar 2022 | - | $113.76M(+25.0%) |
| Dec 2021 | $90.97M(-6.9%) | $90.97M(-18.8%) |
| Sep 2021 | - | $112.10M(-26.8%) |
| Jun 2021 | - | $153.20M(+73.3%) |
| Mar 2021 | - | $88.39M(-9.6%) |
| Dec 2020 | $97.73M(+64.4%) | $97.73M(+56.2%) |
| Sep 2020 | - | $62.55M(+67.2%) |
| Jun 2020 | - | $37.40M(+25.7%) |
| Mar 2020 | - | $29.75M(-50.0%) |
| Dec 2019 | $59.44M(+98.1%) | $59.44M(+45.9%) |
| Sep 2019 | - | $40.74M(+26.5%) |
| Jun 2019 | - | $32.22M(+14.4%) |
| Mar 2019 | - | $28.16M(-6.1%) |
| Dec 2018 | $30.00M(+35.6%) | $30.00M(+8.5%) |
| Sep 2018 | - | $27.66M(-17.6%) |
| Jun 2018 | - | $33.58M(+26.4%) |
| Mar 2018 | - | $26.57M(+20.1%) |
| Dec 2017 | $22.13M(+41.2%) | $22.13M(+50.6%) |
| Sep 2017 | - | $14.70M(+1.5%) |
| Jun 2017 | - | $14.47M(+16.2%) |
| Mar 2017 | - | $12.45M(-20.6%) |
| Dec 2016 | $15.68M(-51.6%) | $15.68M(-11.3%) |
| Sep 2016 | - | $17.68M(-23.9%) |
| Jun 2016 | - | $23.23M(-9.1%) |
| Mar 2016 | - | $25.54M(-21.2%) |
| Dec 2015 | $32.41M(+254.2%) | $32.41M(+286.2%) |
| Sep 2015 | - | $8.39M(-13.8%) |
| Jun 2015 | - | $9.74M(+26.1%) |
| Mar 2015 | - | $7.72M(-15.6%) |
| Dec 2014 | $9.15M | $9.15M(+10.6%) |
| Sep 2014 | - | $8.28M(-35.8%) |
| Jun 2014 | - | $12.89M(+17.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $10.96M(+20.4%) |
| Dec 2013 | $9.10M(-42.1%) | $9.10M(-62.9%) |
| Sep 2013 | - | $24.52M(+126.4%) |
| Jun 2013 | - | $10.83M(+4.4%) |
| Mar 2013 | - | $10.38M(-33.9%) |
| Dec 2012 | $15.70M(+594.1%) | $15.70M(+251.7%) |
| Sep 2012 | - | $4.46M(-21.5%) |
| Jun 2012 | - | $5.69M(+2.5%) |
| Mar 2012 | - | $5.55M(+145.3%) |
| Dec 2011 | $2.26M(-2.8%) | $2.26M(-63.7%) |
| Sep 2011 | - | $6.24M(+38.7%) |
| Jun 2011 | - | $4.50M(+159.7%) |
| Mar 2011 | - | $1.73M(-25.6%) |
| Dec 2010 | $2.33M(-45.1%) | $2.33M(-11.2%) |
| Sep 2010 | - | $2.62M(+16.3%) |
| Jun 2010 | - | $2.25M(+11.5%) |
| Mar 2010 | - | $2.02M(-52.4%) |
| Dec 2009 | $4.24M(>+9900.0%) | $4.24M(+167.0%) |
| Sep 2009 | - | $1.59M(+78.0%) |
| Jun 2009 | - | $893.10K(+87.3%) |
| Mar 2009 | - | $476.80K(-93.4%) |
| Dec 2008 | $0.00(0.0%) | $7.26M(+385.6%) |
| Sep 2008 | - | $1.50M(+28.8%) |
| Jun 2008 | - | $1.16M(+2.7%) |
| Mar 2008 | - | $1.13M(+45.0%) |
| Dec 2007 | $0.00(0.0%) | $779.80K(+87.0%) |
| Sep 2007 | - | $416.90K(+3.7%) |
| Jun 2007 | - | $401.90K(-27.3%) |
| Mar 2007 | - | $552.80K(+49.4%) |
| Dec 2006 | $0.00(0.0%) | $370.10K(-3.7%) |
| Sep 2006 | - | $384.20K(-4.1%) |
| Jun 2006 | - | $400.70K(+234.8%) |
| Mar 2006 | - | $119.70K(-71.1%) |
| Dec 2005 | $0.00(0.0%) | $413.80K(+901.9%) |
| Sep 2005 | - | $41.30K(-39.1%) |
| Jun 2005 | - | $67.80K(+2160.0%) |
| Dec 2004 | $0.00(0.0%) | - |
| Dec 2003 | $0.00(0.0%) | - |
| Sep 2003 | - | $3000.00(-9.1%) |
| Jun 2003 | - | $3300.00(+94.1%) |
| Mar 2003 | - | $1700.00(>+9900.0%) |
| Dec 2002 | $0.00(0.0%) | - |
| Sep 2002 | - | $0.00(-100.0%) |
| Jun 2002 | - | $200.00(-99.2%) |
| Mar 2002 | - | $24.40K |
| Dec 2001 | $0.00 | - |
FAQ
- What is Halozyme Therapeutics, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. annual accounts receivable year-on-year change?
- What is Halozyme Therapeutics, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. quarterly accounts receivable year-on-year change?
What is Halozyme Therapeutics, Inc. annual accounts receivable?
The current annual accounts receivable of HALO is $308.45M
What is the all time high annual accounts receivable for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high annual accounts receivable is $308.45M
What is Halozyme Therapeutics, Inc. annual accounts receivable year-on-year change?
Over the past year, HALO annual accounts receivable has changed by +$74.25M (+31.70%)
What is Halozyme Therapeutics, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of HALO is $316.34M
What is the all time high quarterly accounts receivable for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high quarterly accounts receivable is $316.34M
What is Halozyme Therapeutics, Inc. quarterly accounts receivable year-on-year change?
Over the past year, HALO quarterly accounts receivable has changed by +$101.81M (+47.46%)